|Description||LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species. It was developed by Eli Lilly and Company and in clinic phase 1 trials with no progress.|
|Synonyms||LY2562175; LY 2562175; LY-2562175;6-(4-((5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid|
|Solubility||10 mM in DMSO|
|Application||LY2562175 has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclinical species.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||740.1±60.0 °C | Condition: Press: 760 Torr|
|Density||1.48±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||LY2562175 was developed by Eli Lilly and Company and in clinic phase 1 trials with no progress.|
DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7...
INT-767, a steride compound, has been found to be a inhibitor of FXR and TGF5 and could have probable effect against some liver and metabolic diseases. It was j...
Chenodeoxycholic Acid is a naturally occurring human bile acid.Chenodeoxycholic acid has been used as medical therapy to dissolve gallstones.
Turofexorate Isopropyl is a highly potent, selective, and orally active farnesoid X receptor (FXR) agonist.
Fexaramine is a small molecule farnesoid X receptor agonist with 100-fold increased affinity relative to natural compounds.
LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclin...
BAR502 is a dual FXR and GPBAR1 agonist (IC50= 2 μM and 0.4 μM for FXR and GPBAR1, respectively).
Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. It reduced liver fat and reverted cholestasis in a rat model.